ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 015,61
0,24%
Dow Jones
38 852,27
0,46%
DAX
18 248,14
0,42%
Brent Oil
83,48
0,01%
Bitcoin
64 206,64
1,65%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) Actualités

CALT Calliditas Therapeutics AB

20,13
0,00 (0,00%)
Avant marché
Dernière mise à jour : 10:29:13
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Calliditas Therapeutics AB CALT NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 20,13 10:29:13
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
20,13
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
06/5/202408:16PRNUSCalliditas announces positive topline results of Phase 2..
06/5/202408:11PRNUSCalliditas announces positive topline results of Phase 2..
24/4/202419:35PRNUSCalliditas Therapeutics' 2023 Annual Report Published
24/4/202419:26PRNUSCalliditas Therapeutics' 2023 Annual Report Published
24/4/202409:30PRNUSCalliditas Announces Positive NefIgArd Open Label Extension..
24/4/202409:26PRNUSCalliditas Announces Positive NefIgArd Open Label Extension..
18/4/202413:13PRNUSCalliditas Therapeutics Presents Additional Data Analyses..
18/4/202413:10PRNUSCalliditas Therapeutics Presents Additional Data Analyses..
09/4/202413:24PRNUSCalliditas Therapeutics to Attend Conferences in April
09/4/202413:22PRNUSCalliditas Therapeutics to Attend Conferences in April
08/4/202414:38PRNUSCalliditas Therapeutics to Present Nefecon Data at the ISN..
08/4/202414:32PRNUSCalliditas Therapeutics to Present Nefecon Data at the ISN..
08/4/202409:24PRNUSCalliditas receives notice of allowance for United States..
08/4/202409:22PRNUSCalliditas receives notice of allowance for United States..
12/3/202402:28PRNUSEverest Medicines' Partner Calliditas Therapeutics Announces..
06/3/202408:38PRNUSCalliditas announces an additional seven year orphan drug..
06/3/202408:34PRNUSCalliditas announces an additional seven year orphan drug..
01/3/202413:43PRNUSCalliditas Therapeutics to Attend Investor Conferences in..
01/3/202413:39PRNUSCalliditas Therapeutics to Attend Investor Conferences in..
21/2/202407:45PRNUSCalliditas Year-end report, January - December 2023
21/2/202407:43PRNUSCalliditas Year-end report, January - December 2023
14/2/202407:11PRNUSInvitation to the presentation of Calliditas´ Year-end..
14/2/202407:09PRNUSInvitation to the presentation of Calliditas´ Year-end..
13/2/202417:28PRNUSCalliditas provides patent update
13/2/202417:26PRNUSCalliditas provides patent update
08/1/202414:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202408:33PRNUSCalliditas Therapeutics provides business update ahead of JP..
08/1/202408:31PRNUSCalliditas Therapeutics provides business update ahead of JP..
07/1/202417:21PRNUSCalliditas Therapeutics appoints Maria Törnsén as President..
07/1/202417:19PRNUSCalliditas Therapeutics appoints Maria Törnsén as President..
07/1/202417:07PRNUSCalliditas to present at JP Morgan Healthcare Conference
07/1/202417:05PRNUSCalliditas to present at JP Morgan Healthcare Conference
27/12/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/12/202318:22PRNUSCalliditas refinances existing term loan with Euro 92..
27/12/202318:16PRNUSCalliditas refinances existing term loan with Euro 92..
21/12/202301:00DJNStocks to Watch: Micron, Warner Bros. Discovery, Paramount..
20/12/202323:33DJNCalliditas Therapeutics Shares Rise 33% After FDA Approves..
20/12/202323:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202322:34PRNUSCalliditas Therapeutics announces full FDA approval of..
20/12/202322:33PRNUSCalliditas Therapeutics announces full FDA approval of..
11/12/202315:40PRNUSCalliditas Receives Notice of Allowance for United States..
11/12/202315:38PRNUSCalliditas Receives Notice of Allowance for United States..
01/12/202309:27PRNUSCalliditas announces additions to the management team
01/12/202309:21PRNUSCalliditas announces additions to the management team
30/11/202308:55PRNUSCalliditas initiates clinical study to evaluate setanaxib in..
30/11/202308:49PRNUSCalliditas initiates clinical study to evaluate setanaxib in..
24/11/202309:13PRNUSCalliditas' partner Everest Medicines announces China NMPA's..
24/11/202309:10PRNUSCalliditas' partner Everest Medicines announces China NMPA's..
07/11/202316:31PRNUSCalliditas to present at upcoming investor conferences
07/11/202316:29PRNUSCalliditas to present at upcoming investor conferences

Dernières Valeurs Consultées

NASDAQ
CALT
Calliditas Therapeutics AB
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés